Joy et al. Disease activity rather than steroid use increases risk of diabetes in RA in BeST study over 10 years. @RheumNow #ACR22 Abstr#1987 https://t.co/VT2eb3Q4m9 https://t.co/kquZ70o9bU

• Prednisone Use and the Incidence of Hyperglycemia or Diabetes in Patients with …

Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year. No difference in RA development. Delay in ACPA+ or high risk. Sustained benefit in MTX group on pain, EMS, function, MRI. @RheumNow #ACR22 Abstr#1603 https://t.co/M2qQfgrhC1 https://t.co/UUeknTLx0K

• Intervention with Methotrexate in Arthralgia at Risk for Rheumatoid Arthritis t…

Does curcurmin (tumeric) do anything in RA? Big talk & sales. Best chance would be keeping pts in remission during csDMARD taper: DBRCT n=200 52w, high bioavail form, good serum conc Absolutely nothing vs placebo I'll call it: just doesn't work in RA ABST1587 #ACR22 @RheumNow https://t.co/wecEfkXT55

Wipfler et al. 1 in 17 individuals prescibed MTX experienced an unexpected barrier in Post-Roe era. @RheumNow #ACR22 Abstr#L09 https://t.co/a8RDZF3JKy https://t.co/cyxJj2adgw

• Impact on Access to Methotrexate in the Post-Roe Era - ACR Meeting Abstracts

#ACR22 Abstr#1756 More data on safety of #COVID vaccine to cite when counselling patients with inflammatory arthritis (IA). Data from COVAX registry (over 7000 pts) showed rates of serious adverse event was low 0.3% vs 2.5% in those with non-IA RMD group @RheumNow https://t.co/iucDK1GpU4

Deane et al STOP RA trial. DBRCT HCQ vs PBO pre-RA. Treat 1 year, stop, 2 year follow up. Does not prevent RA development. Literally no effect at all, even during treatment phase. @RheumNow #ACR22 Abstr#1604 https://t.co/7jHv7cs5DT https://t.co/GNblKs90RU

• Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthri…

Charlton et al PsA patients face longer diagnostic delay and less intensive treatment than RA patients for equivalent disease activity. @RheumNow #ACR22 Abstr#1613 https://t.co/HedK59QsKs https://t.co/xaJUy7w1t4

• Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis…

Preventing #rheumatoid #arthritis - the holy grail! STOPRA RCT of strong ACPA+; CCP3 high titre. No inflammatory arthritis. RCT of #Hydroxychloroquine vs placebo, N=142 Pts. At 3 yrs NO DIFF in onset@of RA in each group. identical curves. Abst1604 #ACR22 #ACRBest @RheumNow Darn! https://t.co/bEgbkxGSR4

Abs 1417 finds physicians prefer ABA over TNFi for RF/ACPA+ pts w/ higher disease severity, older age, the presence of extra-articular manifestations, and comorbidities such as heart failure. My question: Trouble getting it first line? #ACR22 @RheumNow https://t.co/tlFMgjgDNM https://t.co/ukoeLgSSUd

• Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and Firs…

In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effectiveness outcomes between ETN, ADA, and JAKi monotherapy. #ACR22 @RheumNow https://t.co/e8GA45Rrmd https://t.co/zooGxlTftO

• Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etan…